Literature DB >> 15788316

Compliance of Dutch orthopedic departments with national guidelines on thromboprophylaxis. A survey of Dutch orthopedic thromboprohylaxis.

Harmen B Ettema1, Marnix R Hoppener, Christiaan P Henny, Harry R Büller, Cees C P M Verheyen.   

Abstract

All 110 Dutch orthopedic departments were sent a survey on perioperative thromboprophylaxis protocols, and 79% responded. After hip and knee replacements, all used pharmacological thromboprophylaxis: a low-molecular weight heparin (LMWH) in 87% of departments, which was most often combined with vitamin K antagonists (VKAs). LMWH was usually started preoperatively (91%). After discharge, VKAs were mostly prescribed (79%) for at least 6 weeks, and often for 3 months. 17% of departments used LMWH for 6 weeks, whereas in only 3% no post-discharge prophylaxis was given. In day-care surgery, including arthroscopies, 58% use LMWH and in short-stay surgery 80% administer LMWH during the hospital stay. Because of lack of conclusive evidence for day-care surgery, the national guidelines cannot support pharmacological prophylaxis in this setting. In general, Dutch orthopedic departments comply poorly with the national guidelines on extended thromboprophylaxis for hip and knee replacement surgery, which recommends postoperative LMWH for 6 weeks. They are divided in the use of pharmacological prophylaxis in day-care surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788316     DOI: 10.1080/00016470510030409

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


  2 in total

1.  From evidence to action: Understanding clinical practice guidelines.

Authors:  Rudolf W Poolman; Cees C P M Verheyen; Gino M Kerkhoffs; Mohit Bhandari; Holger J Schünemann
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

2.  Dutch orthopedic thromboprophylaxis: a 5-year follow-up survey.

Authors:  Harmen B Ettema; Marieke C Mulder; Michael T Nurmohamed; Harry R Büller; Cees C P M Verheyen
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.